The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Open accessAbstract
Patients ≥ 70 years of age with acute myeloid leukemia (AML) have a poor prognosis. Recent studies suggested that intensive AML-type therapy is tolerated and may benefit most. We analyzed 446 patients ≥ 70 years of age with AML (≥ 20% blasts) treated with cytarabine-based intensive chemotherapy between 1990 and 2008 to identify risk groups for high induction (8-week) mortality. Excluding patients with favorable karyotypes, the overall complete response rate was 45%, 4-week mortality was 26%, and 8-week mortality was 36%. The median survival was 4.6 months, and the 1-year survival rate was 28%. Survival was similar among patients treated before 2000 and since 2000. A multivariate analysis of prognostic factors for 8-week mortality identified the following to be independently adverse: age ≥ 80 years, complex karyotypes, (≥ 3 abnormalities), poor performance (2-4 Eastern Cooperative Oncology Group), and elevated creatinine > 1.3 mg/dL. Patients with none (28%), 1 (40%), 2 (23%), or ≥ 3 factors (9%) had estimated 8-week mortality rates of 16%, 31%, 55%, and 71% respectively. The 8-week mortality model also predicted for differences in complete response and survival rates. In summary, the prognosis of most patients (72%) ≥ 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ≥ 30%; median survival < 6 months).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citationDombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Self-citationWei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Metadata
- Authors
- Kantarjian, H., Ravandi, F., O'Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., Jabbour, E., Wierda, W., Kadia, T., Pierce, S., Shan, J., Keating, M., & Freireich, E. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-11-25
- Volume
- 116
- Issue
- 22
- Pages
- 4422-4429
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2051987542
- Cited by
- 403
- References
- 44
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2010-03-276485
- The paper
- Kantarjian, H., Ravandi, F., O'Brien, S., Cortes, J., Faderl, S., Garcia-Manero, G., Jabbour, E., Wierda, W., Kadia, T., Pierce, S., Shan, J., Keating, M., & Freireich, E. J. (2010). Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2010-03-276485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
